What is OneOme?
Headquartered in Minneapolis, Minnesota, OneOme provides an end-to-end platform designed to facilitate the adoption of pharmacogenomics across the healthcare continuum. By leveraging advanced laboratory testing, sophisticated population-level analytics, and robust software support, the company enables stakeholders to optimize medication management and improve patient outcomes. Co-founded by the Mayo Clinic, OneOme operates at the intersection of clinical research and enterprise health technology, offering tools that help institutions reduce the total cost of care while enhancing the precision of therapeutic interventions. Its market position is defined by its ability to translate complex genomic data into intuitive, bedside-ready insights for clinicians.
How much funding has OneOme raised?
OneOme has raised a total of $4.3M across 4 funding rounds:
Unspecified
$1M
Private Equity
$530K
Debt
$2.1M
Debt
$611K
Unspecified (2015): $1M, investors not publicly disclosed
Private Equity (2016): $530K, investors not publicly disclosed
Debt (2016): $2.1M, investors not publicly disclosed
Debt (2021): $611K featuring PPP
Key Investors in OneOme
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer providing capital to support the long-term development and market expansion of the company's pharmacogenomics platform.
Undisclosed Investor
A strategic partner providing debt-based financing to bolster the company's balance sheet and support ongoing technological innovation.
What's next for OneOme?
With the support of its latest capital injection, OneOme is well-positioned to scale its enterprise-level operations and expand its footprint in the global healthcare market. The company is expected to prioritize the enhancement of its clinical decision support software, ensuring that its analytics engine remains at the forefront of the rapidly evolving pharmacogenomics sector. By focusing on the integration of its platform into existing electronic health record systems, OneOme aims to drive broader adoption of precision medicine, ultimately shifting the industry toward a more proactive, personalized model of patient care that prioritizes long-term health outcomes over reactive treatment protocols.
See full OneOme company page
